Corporate Learning Technology Company Attensi Announces $26m Investment From Lugard Road Capital, DX Ventures, and Viking Venture for Global Expansion
Corporate Learning and Development (L&D) technology innovator Attensi is executing its plans for global expansion after raising $26m from New York-based Lugard Road Capital, DX Ventures, and existing share holder Viking Venture. The investment follows several years of rapid growth for the company, during which Attensi has recorded a 63% CAGR in annual recurring revenue and executed projects for a wide range of international blue-chip customers. The new funding will be used by Attensi to extend its presence in North America and Europe and to expand upon its leading product suite and technology platform in gamified simulations.
“Attensi solutions enable organizations to upskill their people faster, consistently, at scale, with results beyond the capabilities of traditional methods like e-learning, video, or classroom training. With gamified simulation training, we have combined the best of workplace psychology with our expertise in simulations and gamification to create a new category of training solutions. Our gamified simulations create significant real-world impact on companies’ core business metrics,” said Attensi Co-Founder and Co-CEO, Trond Aas. “This funding round enables our ambitious growth plans. With Lugard Road Capital we are bringing in a major US investor with experience of growing SaaS companies into global brands.”
With a client base that includes Daimler Mercedes Benz, Circle K, Equinor, BCG, and ASDA, Attensi uses a fusion of technology from the world of video gaming and insights from workplace psychology to train people via immersive, 3D simulations of their workplace and work processes. At the end of last year, the company announced plans to further develop its technology platform and enter new markets by the end of 2021. The fundraise from Lugard Road Capital, DX Ventures, and Viking Venture represents an acceleration of these plans.
Anne-Lise Waal, CTO and Co-CEO at Attensi said: “This is exciting news for everyone at Attensi. With the Attensi Technology Platform users across the globe can create high-end gamified solutions with our powerful no-code toolset. This investment will be instrumental in further expanding our cloud native SaaS platform and product suite. The Attensi Technology Platform will equip companies across all sectors to deliver on the challenge of continuous development and upskilling of their workforce. Our current plans for organizational expansion will see our staff count grow rapidly from the current level of 120 to well over 200.”
Doug Friedman, partner at Lugard Road Capital, said: “We could not be more excited to be investing in the Attensi team as they work to forever change and improve corporate learning and development through their Attensi solutions.”
Duncan McIntyre, Managing Director at DX Ventures, said: “Learning and development opportunities are becoming a decisive competitive factor to improve performance, attract and retain talent. We are thrilled to support Attensi to achieve its mission to make corporate training more effective and engaging.”
Eivind Bergsmyr, partner at Viking Venture, commented: “It’s been exciting to see the rapid growth and impressive development driven by the ability to bring in global top brands as customers during our time as investor in Attensi. This capital raise expands the investor universe with investors we know well from other Viking Venture portfolio companies and allows Attensi to continue its global expansion at increased pace.”
Established in 2012, Attensi has delivered gamified simulation training in more than 100 countries in 20 languages. Attensi solutions are used to simulate human interactions and work processes, including interpersonal ‘soft skills’, leadership training, use of IT-systems and any form of staff certification. Whether on mobile, desktop, or VR, Attensi’s gamified simulation approach enables organizations to upskill their people effectively, consistently, at scale, with all the data required to track impact on KPIs.
Attensi clients are corporate blue-chip companies in health care, pharmaceutical, financial services, professional services, retail, hospitality, manufacturing, shipping, offshore and transport, as well as public and third sectors. The company’s total revenue annual run-rate is currently $12m, and is headquartered in Oslo, Norway, with offices in London, UK, and Palo Alto, USA.
Pareto was engaged as Global Coordinator for the equity issue. GCA Altium is acting as the Global Financial Advisor to the company. Thommessen acted as the legal advisor in the transaction.
ENDS
Notes to editors:
About Attensi
Driven by the best of psychology, learning, and gaming, Attensi gamified simulation training engages your people with measurable impact on your KPIs. Whether on mobile, desktop, or VR, Attensi solutions empower people to learn new skills and behaviours in a fun, engaging way. The results enable organizations to excel in staff training, onboarding, and retention.
Attensi has delivered gamified simulation training in more than 100 countries, in 20 languages, and employs over 100 staff. Attensi is headquartered in Oslo, Norway, with offices in London, and Palo Alto, USA.
About Viking Venture
Viking Venture is the leading Nordic Software investor with more than NOK 3 billion under management. Since 2001, Viking Venture has invested in more than 50 Nordic companies with a particular focus on scaling Business-to-business (B2B) Software-as-a-Service (SaaS) companies. Viking Venture has been the lead investor of Attensi since 2018.
About Lugard Road Capital
Lugard Road Capital is a multi-billion-dollar global investment fund primarily focused on public and private companies in the Internet, software, consumer, and technology sectors.
About DX Ventures
DX Ventures is a venture capital fund backed by Delivery Hero. The fund’s mission is to support the next generation of founder-led companies that are disrupting some of the most rapidly changing industries around the world. The investment philosophy is centered on building long term partnerships with founders to provide support throughout the lifecycle and actively create value.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210408005063/en/
Contact information
Media:
Steve Maybury | steve@opr.co.uk | +44 (0)7985774743
Aranda Rahbarkouhi | aranda@opr.co.uk | +44 (0)7807009347
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Merz Therapeutics to Present Broad Range of Clinical, Real-World and Mechanistic Data at TOXINS 20268.12.2025 09:00:00 EET | Press release
Merz Therapeutics, a leading player in neurology-focused specialty pharma, today announced that the company will present more than 20 clinical and non-clinical abstracts and posters spanning spasticity, movement disorders, and neurotoxin science at the TOXINS 2026 8th International Conference, taking place January 14–17, 2026, in Madrid, Spain. These presentations underscore the company’s commitment to addressing unmet needs in neurological disorders. “Our research reflects a relentless focus on improving patient outcomes through innovation in neurotoxin science,” said Dr. Stefan Albrecht, Chief Scientific and Medical Officer at Merz Therapeutics. “By presenting these new data at TOXINS 2026, we aim to foster scientific exchange and advance treatment strategies that address real-world challenges for patients and clinicians.” Merz Therapeutics will share new findings reflecting its continued dedication to advancing neurotoxin science. These include: Lower Limb Spasticity Incobotulinumto
Galderma Welcomes Increased Equity Investment From L’Oréal8.12.2025 08:05:00 EET | Press release
Galderma Group AG (SIX:GALD), the pure-play dermatology category leader, today announced that L’Oréal Groupe intends to increase its equity investment in the company, acquiring an additional 10% stake from Sunshine SwissCo GmbH (a consortium led by EQT, Abu Dhabi Investment Authority (ADIA), and Auba Investment Pte. Ltd., acting as sellers). Following the transaction, which is subject to customary approvals, L’Oréal’s total shareholding in Galderma will rise to 20%, building on its initial investment made in August 2024. The transaction is expected to close in Q1 2026. In connection with this increased investment, Galderma will consider nominating two non-independent board candidates from L’Oréal, replacing the board members representing the consortium led by EQT, at the 2026 Annual General Meeting. Additionally, Galderma and L’Oréal aim at exploring additional scientific research projects of mutual interest. This ongoing collaboration brings together Galderma’s scientific leadership i
Ant International Wins Champion of NeurIPS Competition of Fairness in AI Face Detection8.12.2025 05:37:00 EET | Press release
Ant International, a leading global digital payment, digitisation, and financial technology provider, has won first place at the NeurIPS Competition of Fairness in AI Face Detection. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207210856/en/ Ant International’s solution takes top spot at the NeurIPS Competition of Fairness in AI Face Detection, emerging first among over 2,100 submissions from 162 teams globally. AI Fairness enhances Financial Security Studies by the National Institute of Standards and Technology (NIST) show that many commercial facial recognition algorithms have significantly higher error rates for women and people of colour largely due to underrepresentation in datasets AI algorithms are trained on. Biased algorithms lead to unfair denials of service and create security vulnerabilities. The competition at the Conference on Neural Information Processing Systems, among the world’s most prestigious AI con
Sonrotoclax Data at ASH 2025 Confirm Foundational Potential Across B-cell Malignancies8.12.2025 01:00:00 EET | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data on sonrotoclax, a next-generation investigational BCL2 inhibitor, demonstrating meaningful clinical benefit as monotherapy and in combination across B-cell malignancies. These data were featured at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition in Orlando, Florida. The five presentations highlight durable responses in heavily pretreated patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) and additional studies showing deep, rapid, and sustained undetectable minimal residual disease (uMRD) rates with sonrotoclax-based combinations in patients with treatment-naive chronic lymphocytic leukemia (CLL), highlighting the foundational potential of this medicine. “The data we’re presenting at ASH 2025 are redefining what physicians can expect from sonrotoclax as a next-generation BCL2 inhibitor,” said Amit Agarwal, M.D., Ph.D., Chief Medical
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 18:00:00 EET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
